Indoline compound and 5-ht3 receptor antagonist containing the same as active ingredient
CA 2173155 A1 · Owner: Tt Pharmaceuticals, Inc. · Inventors: Tsuchiya, Shinji; Fukuzaki, Atsushi; Kazama, Koichi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An indoline compound represented by general formula (I); a physiologically acceptable salt thereof; solvates of theses compounds; and a 5-HT3 receptor antagonist containing the same as the active ingredient. In formula (I) R1 represents the group (a) or (b), R2 represents optionally substituted phenyl or heteroaryl; and R3 represents hydrogen halogen, lower alkyl, hydroxy, lower alkoxy carbamoyl or lower alkoxycarbonyl. The compound has a potent antagonism against 5-HT3 receptors in the intestinal tract as compared with the known 5-HT3 receptor antagonists and is excellent in the persistence of the activity. Hence it is useful for preventing or treating vomiting or nausea induced by …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 30, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 30, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 30, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.